With regard to the therapy decision, one has to bear in mind that this is not exclusively achieved by molecular-based analysis as for EGFR mutations (Rosell et al, 2009), but also deeply depends upon the previous diagnosis of NSCLC and subdifferentiation into adenocarcinomas. This evidence concerns the gene EGFR and non-small cell lung carcinoma.